What are the management options for acute and chronic gout?

Management of Acute and Chronic Gout

Acute Gout Attack Management

For acute gout attacks, initiate treatment with corticosteroids, NSAIDs, or low-dose colchicine within 24 hours of symptom onset, with the choice depending on patient comorbidities rather than drug superiority. 1, 2

First-Line Treatment Options

• NSAIDs at full anti-inflammatory doses (naproxen 500mg twice daily or indomethacin) should be started immediately and continued until complete resolution of symptoms 1, 3

  • Contraindicated in patients with renal disease (CrCl <30 mL/min), heart failure, cirrhosis, or active peptic ulcer disease 2, 3
  • Most effective when initiated within 24 hours of symptom onset 2

• Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later, maximum 1.8 mg over one hour) is equally effective as high-dose regimens with significantly fewer gastrointestinal side effects 1, 2, 3

  • Most effective when started within 12-36 hours of symptom onset 2, 3
  • Requires dose adjustment in renal impairment (avoid if CrCl <10 mL/min) 2
  • Avoid concurrent use with strong P-glycoprotein or CYP3A4 inhibitors (cyclosporine, clarithromycin) due to risk of severe toxicity 2

• Corticosteroids are particularly useful for patients with contraindications to NSAIDs or colchicine 1, 2, 4

  • Oral prednisone 30-35 mg/day for 3-5 days (or 0.5 mg/kg/day for 5-10 days) 2, 4
  • Intra-articular injection for single joint involvement (highly effective) 2, 3
  • Intramuscular methylprednisolone (0.5-2.0 mg/kg) for NPO patients with polyarticular involvement 2
  • Safest option in patients with renal impairment 2, 4

Treatment Algorithm Based on Clinical Presentation

• For monoarticular involvement: Choose any single first-line agent based on contraindications 2
• For severe pain (≥7/10) or polyarticular involvement: Use combination therapy (colchicine + NSAIDs, oral corticosteroids + colchicine, or intra-articular steroids with any other modality) 2
• For inadequate response (<20% improvement in 24 hours or <50% improvement after 24 hours): Switch to another monotherapy or add a second agent 2

Critical Management Principles

• Continue established urate-lowering therapy without interruption during acute attacks - discontinuation is a common error that worsens outcomes 2, 4
• Topical ice application provides adjunctive benefit 2
• Educate patients on "pill in the pocket" approach to self-medicate at first warning symptoms 2
• Treatment delays beyond 24 hours significantly reduce effectiveness 2, 3

---

Long-Term Management of Chronic Gout

Do not initiate urate-lowering therapy after a first gout attack or in patients with infrequent attacks (<2 per year); reserve it for patients with recurrent attacks, tophi, radiographic changes, or urate nephropathy. 1, 2, 4

Indications for Urate-Lowering Therapy (ULT)

• Recurrent acute gout attacks (≥2 per year) 1, 4
• Presence of tophi (clinical or radiographic) 1, 2, 4
• Radiographic changes of gout 2
• History of urate nephropathy or renal stones 4

First-Line Urate-Lowering Therapy

• Xanthine oxidase inhibitors (allopurinol or febuxostat) are first-line agents 2, 5

  • Start allopurinol at 100 mg daily and increase by 100 mg every 2-4 weeks until target serum urate <6 mg/dL is achieved (maximum 800 mg/day) 1, 4, 5
  • In renal impairment: CrCl 10-20 mL/min use 200 mg/day; CrCl <10 mL/min use maximum 100 mg/day 5
  • Allopurinol is NOT recommended for asymptomatic hyperuricemia 5

• Target serum urate level: <6 mg/dL (below saturation threshold for monosodium urate crystal formation) 2

• Uricosuric agents (probenecid, benzbromarone) are alternatives in patients with normal renal function, no history of urolithiasis, and allopurinol intolerance 2

Mandatory Prophylaxis During ULT Initiation

Anti-inflammatory prophylaxis is essential when starting urate-lowering therapy to prevent acute flares. 1, 2, 4

• Prophylactic options: Low-dose colchicine (0.5-1 mg/day), low-dose NSAIDs with gastroprotection, or low-dose prednisone 2, 3, 4
• Duration: Continue for at least 6 months, OR 3 months after achieving target serum urate if no tophi present, OR 6 months after achieving target serum urate if tophi present 2, 3
• Inadequate prophylaxis duration leads to breakthrough flares and poor medication adherence 2

Monitoring During ULT

• Check serum uric acid levels regularly to guide dose titration 5
• Monitor renal function (eGFR) regularly, especially in patients on allopurinol 4, 5
• Screen for associated comorbidities (coronary heart disease, heart failure, stroke, diabetes) 4
• Maintain fluid intake sufficient to yield daily urinary output of at least 2 liters 5

---

Non-Pharmacologic Measures

• Weight loss for obese patients reduces gout flare risk 2, 4
• Avoid alcoholic drinks (especially beer) and beverages sweetened with high-fructose corn syrup 2, 4
• Limit purine-rich foods (organ meats, shellfish) 4
• Encourage consumption of vegetables and low-fat/nonfat dairy products 4

---

Common Pitfalls and Caveats

• Delaying acute treatment beyond 24 hours dramatically reduces effectiveness 2, 3
• Using high-dose colchicine regimens causes significant gastrointestinal toxicity without additional benefit 1, 2
• Discontinuing ULT during acute flares worsens outcomes and should be avoided 2, 4
• Starting ULT without prophylaxis leads to acute flares and treatment abandonment 2, 4
• Inadequate duration of prophylaxis (<6 months) results in breakthrough flares 2, 3
• Starting allopurinol at high doses increases risk of acute flares; always start at 100 mg/day and titrate slowly 4, 5
• Ignoring renal function when dosing NSAIDs, colchicine, or allopurinol leads to toxicity 2, 4, 5
• Failing to adjust allopurinol dose in renal impairment can cause drug accumulation and adverse effects 5